Clinical Trial Update: PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for PANORAMIX, examining optimization of first-line NALIRIFOX (liposomal irinotecan-based therapy) and investigating the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING